Table 1 Clinical characteristics of patients with NSCLC
Characteristics | Cohort I | Cohort II | p value | Mutations | Training | Test | p value |
|---|---|---|---|---|---|---|---|
Number | 370 (72.8%) | 138 (27.2%) | - | EGFR | 0.203 | ||
Age (years) | ∗ | Mutant | 130 (38.5%) | 56 (38.6%) | |||
mean ± SD | 62.6 \( \pm \) 10.7 | 69.2 \( \pm \) 8.9 | Wildtype | 207 (61.5%) | 89 (61.4%) | ||
Gender | * | KRAS | 0.081 | ||||
Male | 229 (61.9%) | 102 (73.9%) | Mutant | 34 (10.3%) | 23 (16.3%) | ||
Female | 141 (38.1%) | 36 (26.1%) | Wildtype | 295 (89.7%) | 118 (83.7%) | ||
Smoking status | * | ALK | 0.124 | ||||
Smoker | 178 (48.1%) | 116 (84.1%) | Mutant | 14 (4.2%) | 13 (9.0%) | ||
Nonsmoker | 192 (51.9%) | 22 (15.9%) | Wildtype | 317 (95.8%) | 130 (91.0%) | ||
Tumor location | 0.379 | TP53 | 0.904 | ||||
RUL | 110 (29.7%) | 50 (36.2%) | Mutant | 62 (22.9%) | 58 (58.0%) | ||
RML | 34 (9.2%) | 12 (8.7%) | Wildtype | 208 (77.1%) | 42 (42.0%) | ||
RLL | 68 (18.4%) | 21 (15.2%) | PIK3CA | 0.083 | |||
LUL | 110 (29.7%) | 35 (25.4%) | Mutant | 28 (10.8%) | 19 (17.1%) | ||
LLL | 48 (13.0%) | 20 (14.5%) | Wildtype | 231 (89.2%) | 92 (82.9%) | ||
Risk factors | Training | Test | p value | ROS1 | 0.101 | ||
LVI | 0.792 | Mutant | 16 (6.6%) | 10 (8.7%) | |||
Present | 114 (32.1%) | 49 (32.0%) | Wildtype | 240 (93.4%) | 104 (91.3%) | ||
Absent | 241 (67.9%) | 104 (68.0%) | Immune | Training | Test | p value | |
PI | 0.139 | PD-1/PD-L1 | 0.059 | ||||
Yes | 224 (63.1%) | 96 (62.7%) | Positive | 63 (50.4%) | 22 (40.0%) | ||
No | 131 (36.9%) | 57 (37.3%) | Negative | 62 (49.6%) | 33 (60.0%) | ||
T staging | 0.612 | ||||||
T4 | 87 (24.5%) | 37 (24.2%) | |||||
Other | 268 (75.5%) | 116 (75.8%) |